TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15793051

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (standard prophylactic regimen of oral beta blocker)
Number of subjects: 120
Study: 11840182

Group type: EXPERIMENTAL
Intervention: High unsaturated 'modified' butter feeding
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saturated 'control' butter feeding
Number of subjects: 20
Study: 9847434

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 7781487

Group type: EXPERIMENTAL
Intervention: Carbomer gel Lubrithal (Leo viscous eye gel)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyvinyl alcohol (Liquifilm, Allergan)
Number of subjects: 40
Study: 3166361

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 to 2000 mg daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg daily)
Number of subjects: 31
Study: 29724198

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 27290935

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy (FOB)‐guided intubation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) obturated with an inflated esophageal stethoscope
Number of subjects: 44
Study: 24257969

Group type: EXPERIMENTAL
Intervention: Early once‐daily physical therapy plus a novel, progressive, twice‐daily cognitive therapy protocol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Early once‐daily physical therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All groups (Usual care, Early once‐daily physical therapy, Early once‐daily physical therapy plus cognitive therapy)
Number of subjects: 87
Study: 22409388

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 10 μg/h
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 20 μg/h
Number of subjects: 198

Group type: COMPARATOR
Intervention: Vicodin (hydrocodone/acetaminophen)
Number of subjects: 198
Study: 21031292

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation programme
Number of subjects: 741

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 741
Study: 18605968

Group type: EXPERIMENTAL
Intervention: Tight control of hypertension (mean dose of methyldopa 1267±406 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Less tight control of hypertension
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tight control of hypertension
Number of subjects: 125
Study: 16189305

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated Cambridge Cup
Number of subjects: 50

Group type: COMPARATOR
Intervention: Uncoated Cambridge Cup
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated components
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall scores
Number of subjects: 50
Study: 14622489

Group type: EXPERIMENTAL
Intervention: Public decision-making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related comparisons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Private decision-making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthcare professionals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public sample
Number of subjects: 0
Study: 10659898

Group type: EXPERIMENTAL
Intervention: Double-gloving method
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single-gloving method
Number of subjects: 300
Study: 10064358

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion using a PALL medical leukocyte filter during cardiopulmonary bypass
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group with only an arterial line filter without leukodepletion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion using a PALL medical leukocyte filter
Number of subjects: 10
Study: 1486160

Group type: EXPERIMENTAL
Intervention: 0.5 mg flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 6428368

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 23
Study: 31859438

Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stent (O‐SES)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus-eluting stent (R‐ZES)
Number of subjects: 372
Study: 29413240

Group type: EXPERIMENTAL
Intervention: NeoVas BRS
Number of subjects: 560

Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 560
Study: 27277674

Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncuffed tracheal tube
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 24609724

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 32% protein, 41% carbohydrate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC: 20% protein, 58% carbohydrate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both diets (HP and HC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher-protein intake
Number of subjects: 36
Study: 21933335

Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator recommendation for biopsy (P(posb) ≥20%)
Number of subjects: 443

Group type: COMPARATOR
Intervention: ERSPC Risk Calculator recommendation for no biopsy
Number of subjects: 443

Group type: COMPARATOR
Intervention: Biopsy against the recommendation of the RC
Number of subjects: 443

Group type: COMPARATOR
Intervention: Biopsy recommended due to elevated PSA level (≥ 3 ng/mL)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Patient's desire for certainty
Number of subjects: 443
Study: 20535457

Group type: EXPERIMENTAL
Intervention: AZD0837 450 mg extended‐release formulation once daily for 8 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cimetidine co-administered on Days 6‐8 during both treatment periods
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AZD0837
Number of subjects: 30
Study: 17650832

Group type: EXPERIMENTAL
Intervention: High-dose inhaled beclomethasone (1,500 microg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 16271314

Group type: EXPERIMENTAL
Intervention: bupropion XL 150-300 mg
Number of subjects: 1042

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1042
Study: 12142116

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL high-dose group (mean 192 mg)
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL low-dose group (mean 76 mg)
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1614
Study: 10738353

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) with primary stent implantation
Number of subjects: 0
Study: 7755050

Group type: EXPERIMENTAL
Intervention: Neural tube defect group (27 women)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (31 women)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 1968672

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modafinil (after 6 weeks chronic administration)
Number of subjects: 40
Study: 6771137

Group type: EXPERIMENTAL
Intervention: 99mTc‐methylene diophosphonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 99mTc‐ethane hydroxy diphosphonate
Number of subjects: 0
Study: 30685677

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D (CaD) supplementation
Number of subjects: 16801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16801

Group type: EXPERIMENTAL
Intervention: Baseline 25‐hydroxyvitamin D serum levels
Number of subjects: 16801
Study: 28271251

Group type: EXPERIMENTAL
Intervention: Sitagliptin added to metformin
Number of subjects: 5535

Group type: COMPARATOR
Intervention: Glimepiride added to metformin/sitagliptin
Number of subjects: 5535

Group type: COMPARATOR
Intervention: Gliclazide added to metformin/sitagliptin
Number of subjects: 5535

Group type: COMPARATOR
Intervention: Repaglinide added to metformin/sitagliptin
Number of subjects: 5535

Group type: COMPARATOR
Intervention: Acarbose added to metformin/sitagliptin
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Adverse events in dual therapy stage
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Adverse events in triple therapy stage
Number of subjects: 5535
Study: 25661661

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1024
Study: 23822603

Group type: EXPERIMENTAL
Intervention: GLASSIA (alpha1-proteinase inhibitor (human), intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PROLASTIN (alpha1-proteinase inhibitor (human), intravenous)
Number of subjects: 0
Study: 20658527

Group type: EXPERIMENTAL
Intervention: Immunochemical fecal occult blood test (FIT)
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Guaiac fecal occult blood test (G‐FOBT)
Number of subjects: 12537
Study: 19249198

Group type: EXPERIMENTAL
Intervention: Montelukast 10mg/day for 6 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 75
Study: 16409424

Group type: EXPERIMENTAL
Intervention: Thyroxine 100 microg/day for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15221407

Group type: EXPERIMENTAL
Intervention: Topical heat treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Static stretching treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heat plus static stretching treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 11484753

Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study: 9405910

Group type: EXPERIMENTAL
Intervention: GLP-1 tablet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8432269

Group type: EXPERIMENTAL
Intervention: Atracurium 0.23 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by atracurium 0.23 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 and atracurium 0.23 mg kg‐1 in rapid succession
Number of subjects: 30
Study: 3322467

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 38
Study: 31526218

Group type: COMPARATOR
Intervention: Heat-stable rotavirus vaccine (HSRV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparator (RotaTeq®)
Number of subjects: 100
Study: 29181816

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 25
Study: 27537264

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus intravitreal dexamethasone implant (IVC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (IVM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatment groups (IVM and IVC)
Number of subjects: 40
Study: 24846035

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 39 to 234 mg every month
Number of subjects: 311

Group type: COMPARATOR
Intervention: Haloperidol decanoate 25 to 200 mg every month
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 311

Group type: COMPARATOR
Intervention: Haloperidol decanoate
Number of subjects: 311
Study: 21918522

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg) at bedtime
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (no add-on medication)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 605
Study: 21907255

Group type: EXPERIMENTAL
Intervention: Shanchol vaccine
Number of subjects: 3
Study: 18830810

Group type: EXPERIMENTAL
Intervention: PEGASE education program (six hospital-based educational sessions: four collective and two individual)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: PEGASE education program
Number of subjects: 640

Group type: COMPARATOR
Intervention: Non-trained group (no educational sessions)
Number of subjects: 640
Study: 16609067

Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (n = 113)
Number of subjects: 198

Group type: COMPARATOR
Intervention: CHOP therapy (n = 85)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: R-CHOP and CHOP therapy
Number of subjects: 198
Study: 14674501

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (no‐etch technique)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (no‐etch technique)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Syntac Single Component
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NRC/Prime and Bond NT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single Bond (control group)
Number of subjects: 24
Study: 10962411

Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study: 8641510

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal of GnRH‐a treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH‐a treatment
Number of subjects: 0
Study: 1456555

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6610938

Group type: EXPERIMENTAL
Intervention: Early use of anticoagulants or platelet inhibiting agents for about one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less than complete revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 0
Study: 31074821

Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs without a phase 2 trial
Number of subjects: 64600

Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs with a phase 2 trial
Number of subjects: 64600
Study: 29245201

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 50
Study: 26746121

Group type: EXPERIMENTAL
Intervention: 2.5 mg buspirone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 5.0 mg buspirone
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 24007934

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid (Preop(®), 50 kcal/100 ml)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tap water flavoured with lemon (control group, 800 ml + 400 ml)
Number of subjects: 23
Study: 22089860

Group type: EXPERIMENTAL
Intervention: Combination treatment with branched-chain amino acid (BCAA; Livact; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single treatment with BCAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single treatment with ACE-I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with BCAA and ACE-I
Number of subjects: 0
Study: 20629533

Group type: EXPERIMENTAL
Intervention: PNU-100480 (1000 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Linezolid (300 mg)
Number of subjects: 19
Study: 18039363

Group type: EXPERIMENTAL
Intervention: TheoRY-inspired MEssage ('TRY-ME')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short directive message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long insert or no insert
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theory-based outsert or standard outsert or no outsert
Number of subjects: 0
Study: 14745283

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 250 mg b.d. (RLC-1 group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 500 mg b.d. (RLC-2 group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: RLC-1 group
Number of subjects: 100
Study: 11534303

Group type: EXPERIMENTAL
Intervention: 20 IU syntocinon in 20 ml 0.9% NaCl saline intraumbilically (group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 20 ml 0.9% NaCl saline (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.2 mg ergometrine IUV in 20 ml 0.9% NaCl saline (group 3)
Number of subjects: 31
Study: 9918445

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8294678

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, or moricizine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 2725884

Group type: EXPERIMENTAL
Intervention: CY 208-243 (5 to 40 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 4595485

Group type: EXPERIMENTAL
Intervention: Fenfluramine (80-120 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dietary restricted régime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study: 31977910

Group type: EXPERIMENTAL
Intervention: Video playback application (SPSRS), 10-minute intervention per day for 5 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 32
Study: 30120957

Group type: EXPERIMENTAL
Intervention: EUS-guided radiofrequency ablation (EUS-RFA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: EUS-guided celiac plexus neurolysis (EUS-CPN)
Number of subjects: 26
Study: 28060186

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Electroencephalogram spectral power distributions
Number of subjects: 15
Study: 24844542

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with goniosynechialysis (phaco-GSL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phacoemulsification (phaco)
Number of subjects: 43
Study: 22886553

Group type: EXPERIMENTAL
Intervention: In-hospital exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 20
Study: 22325227

Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy (Nedaplatin 30 mg/m2 IV once weekly for 4 to 5 weeks + Megestrol 160 mg orally daily during radiation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 42
Study: 19544782

Group type: EXPERIMENTAL
Intervention: Online reoptimization (adapt) with 5 mm PTV margin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bony-anatomy matching (bone10) with 10 mm PTV margin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soft-tissue matching (soft10) with 10 mm PTV margin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soft-tissue matching (soft5) with 5 mm PTV margin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Online reoptimization (adapt) vs new plan
Number of subjects: 6
Study: 16672046

Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine (Dobatro: up to 40 mcg/kg/min i.v. dobutamine with addition of up to 1 mg of atropine)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dipyridamole-atropine (Dipatro: 0.84 mg/kg over 10 min i.v. dipyridamole with addition of up to 1 mg of atropine)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Exercise (Ex, Bruce)
Number of subjects: 117
Study: 15911161

Group type: COMPARATOR
Intervention: Rectal placebo (RP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rectal lidocaine (RL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Natural history (NH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (placebo effect)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Naloxone (to test naloxone antagonism of the placebo effect)
Number of subjects: 26
Study: 12150499

Group type: EXPERIMENTAL
Intervention: 10-100 mg sildenafil
Number of subjects: 781

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 781
Study: 10458714

Group type: EXPERIMENTAL
Intervention: abciximab (12-hour administration)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: abciximab (24-hour administration)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 7789047

Group type: EXPERIMENTAL
Intervention: Nebulized inhaled morphine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulized inhaled morphine 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 2.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 1.0 mg
Number of subjects: 12
Study: 2365189

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 112) - predictive model based on clinical features and laboratory values
Number of subjects: 225

Group type: COMPARATOR
Intervention: Group 2 (n = 113) - cross-validation of predictive model
Number of subjects: 225
Study: 330353

Group type: EXPERIMENTAL
Intervention: 15 S‐15 methyl PGE2 methyl ester
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 15 R‐15 methyl PGE2 methyl ester
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 30768369

Group type: EXPERIMENTAL
Intervention: napabucasin plus nab-paclitaxel with gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: nab-paclitaxel with gemcitabine
Number of subjects: 0